Previous 10 | Next 10 |
Do You Have These Top Biotech Stocks On Your Watchlist? Depending on your investment appetite, the stock market offers various types of opportunities. Biotech stocks have a reputation for being a high-risk, high-reward sector to invest in. This is an industry that includes compa...
Global Blood Therapeutics (NASDAQ:GBT) may be a potential acquisition candidate in the biotech space following Pfizer (PFE)'s deal to acquire Biohaven Pharmaceutical for about $11.6 billion, according to a Wedbush analyst. "In light of Pfizer’s $12 billion acquisition of Biohaven Pharm...
Biohaven Pharmaceuticals Holding Company Ltd. ( NYSE: BHVN ) was up 70% after the company and Pfizer Inc. ( NYSE: PFE ) entered a definitive agreement under which Pfizer would acquire the NURTEC ODT maker. NURTEC ODT is a novel dual-acting medicine for migraine that is l...
NEW YORK, NY / ACCESSWIRE / May 11, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ServiceSource International, Inc. (NA...
The major U.S. equity indices put in a mixed performance on Tuesday, stabilizing after the declines that have rocked Wall Street in recent days. The S&P 500 and Nasdaq finished higher, while the Dow posted mild losses. Food distribution stocks were among the gainers on the day. Strong ear...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Based in New Haven, Connecticut, biotech company Biohaven Pharmaceutical (NYSE: BHVN ) is soaring today after announcing its acquisition by Pfizer (NYSE: PFE ). Currently, BHVN stock is up nearly 70% on a...
Shares of Biohaven Pharmaceutical (NYSE: BHVN) rocketed 68% on Tuesday after the biopharmaceutical company struck a deal to be acquired by Pfizer (NYSE: PFE) . Biohaven is a leader in the treatment of migraines -- often intensely painful headaches that affect 1 billion p...
Despite a slew of investment houses cutting price targets for CRISPR Therapeutics (NASDAQ:CRSP) Tuesday in the wake of its Q1 2022 results, shares closed up 9%. One reason for the rise is social media speculation that following Pfizer's (PFE) announcement Tuesday it would acquire Biohave...
Investors came into Tuesday's trading session hoping to get some relief from the short-term declines that the stock market has suffered lately. Unfortunately, early gains proved short-lived, and several major market benchmarks moved back into negative territory amid ongoing concerns about t...
Stock Market Today Mid-Morning Updates On Tuesday, the Dow Jones Industrial Average is up by 350 points after retreating for the last 3 sessions. All major indexes were green today despite continued fears of rising inflation. Also, rising interest rates continue to weigh in on i...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...
2024-05-29 11:00:21 ET Leonid Timashev from RBC Capital issued a price target of $59.00 for BHVN on 2024-05-29 09:14:00. The adjusted price target was set to $59.00. At the time of the announcement, BHVN was trading at $28.69. The overall price target consensus is at $23...